ChemExpress Subsidiary Clears U.S. FDA Inspection to Expand American Market Access

Shanghai, Tuesday, 18 August 2026.
ChemExpress subsidiary 2Y-Biopharma achieved a flawless U.S. FDA pre-approval inspection with zero citations, paving the way to manufacture and export commercial drug products into the American market.